Skip to main content
    E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $47.62
    -1.18 (-2.42%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enliven Therapeutics Inc. (ELVN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Enliven Therapeutics (ELVN) to earn -$1.67 per share in the fiscal year ending Dec 31, 2026. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.79, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy321.4%
    Buy1178.6%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$1.67
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.99
    EPS consensus, revenue $5000
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.67-$2.25 to -$1.168N/AN/A10
    Dec 31, 2027-$1.99-$2.43 to -$1.578$5000N/A10

    Quarterly Estimates

    The EPS consensus rises from -$0.53 for the quarter ending Dec 31, 2026 to -$0.46 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.53-$0.68 to -$0.4216
    Mar 31, 2027-$0.46-$0.54 to -$0.425

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.97.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.67-$1.91-$1.93-$1.85-$1.97N/A
    Fiscal year ending Dec 31, 2027-$1.99-$2.32-$2.35-$2.34-$2.30N/A
    Quarter ending Mar 31, 2027-$0.46-$0.53-$0.54-$0.53-$0.54N/A

    Frequently Asked Questions About ELVN

    What is the ELVN stock forecast?

    Consensus analyst estimates put Enliven Therapeutics's EPS at -$1.67 for the fiscal year ending Dec 31, 2026. The consensus rating from 14 analysts is Buy.

    How do analysts rate ELVN stock?

    Of 14 analysts covering Enliven Therapeutics, 3 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ELVN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.67, with estimates from -$2.25 to -$1.16 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.99, with estimates from -$2.43 to -$1.57 from 8 analysts.

    What revenue do analysts expect from Enliven Therapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5000.

    How many analysts cover ELVN?

    14 analysts rate Enliven Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.